ETTX insider filings
Entasis Therapeutics Holdings Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-07-13. Screen ETTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ETTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Entasis Therapeutics Holdings Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-07-13 | 4 | Innoviva, Inc. — 10% owner Innoviva Strategic Opportunities LLC | Purchase (P): 11,671,662 @ $2.20 · Purchase (P): 7,598,814 @ $2.20 | EDGAR |
| 2022-07-11 | 4 | Wagner Kristie Ann — VP, Principal Fin & Acct Off | Disposition to issuer (D): 80,500 · Other (J): 73,400 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Triola Anna Diaz — Chief Commercial Officer | Disposition to issuer (D): 125,000 · Other (J): 100,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Tommasi Ruben — Chief Scientific Officer | Code (U): 39,596 @ $2.20 · Disposition to issuer (D): 150,000 · Other (J): 98,700 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 · Other (J): 24,858 (derivative) @ $0 · Other (J): 6,465 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Ronsheim Matthew — Chief of Pharma Sciences & MFG | Code (U): 17,572 @ $2.20 · Disposition to issuer (D): 150,000 · Other (J): 33,333 (derivative) @ $0 · Other (J): 20,000 (derivative) @ $0 · Other (J): 15,000 (derivative) @ $0 · Other (J): 20,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Perros Manoussos — President and CEO, Director | Code (U): 56,072 @ $2.20 · Disposition to issuer (D): 478,500 · Other (J): 325,755 (derivative) @ $0 · Other (J): 145,000 (derivative) @ $0 · Other (J): 183,013 (derivative) @ $0 · Other (J): 69,970 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Mueller John Patrick — Chief Development Officer | Code (U): 17,092 @ $2.20 · Disposition to issuer (D): 150,000 · Other (J): 75,698 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 · Other (J): 25,092 (derivative) @ $0 · Other (J): 18,253 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Berger Heather A. — Director | Code (U): 22,000 @ $2.20 · Disposition to issuer (D): 27,500 @ $2.20 · Other (J): 17,307 (derivative) @ $0 · Other (J): 11,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Altarac David — Chief Medical Officer | Code (U): 17,572 @ $2.20 · Disposition to issuer (D): 150,000 · Other (J): 92,307 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Mayer Howard — Director | Code (U): 22,000 @ $2.20 · Disposition to issuer (D): 27,500 @ $2.20 · Other (J): 12,500 (derivative) @ $0 · Other (J): 11,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Keiley Elizabeth M — General Counsel | Code (U): 17,572 @ $2.20 · Disposition to issuer (D): 150,000 · Other (J): 20,833 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | Meek David D. — Director | Code (U): 22,000 @ $2.20 · Disposition to issuer (D): 27,500 @ $2.20 · Other (J): 17,307 (derivative) @ $0 · Other (J): 11,000 (derivative) @ $0 | EDGAR |
| 2022-07-11 | 4 | HASTINGS DAVID C — Director | Code (U): 22,000 @ $2.20 · Disposition to issuer (D): 27,500 @ $2.20 · Other (J): 26,583 (derivative) @ $0 · Other (J): 11,000 (derivative) @ $0 | EDGAR |
| 2022-02-25 | 4 | Wagner Kristie Ann — VP, Principal Fin & Acct Off | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2022-02-23 | 4 | Innoviva, Inc. — 10% owner Innoviva Strategic Opportunities LLC — Director, 10% owner | Other (J): 0 (derivative) · Other (J): 0 (derivative) | EDGAR |
| 2022-02-15 | 4 | Mueller John Patrick — Chief Development Officer | Disposition to issuer (D): 22,816 (derivative) · Grant/award (A): 15,210 (derivative) · Disposition to issuer (D): 16,892 (derivative) · Grant/award (A): 12,993 (derivative) · Disposition to issuer (D): 7,265 (derivative) · Grant/award (A): 4,035 (derivative) · +2 more | EDGAR |
| 2022-02-15 | 4 | Tommasi Ruben — Chief Scientific Officer | Disposition to issuer (D): 22,816 (derivative) · Grant/award (A): 15,210 (derivative) · Disposition to issuer (D): 15,632 (derivative) · Grant/award (A): 12,024 (derivative) · Disposition to issuer (D): 50,411 (derivative) · Grant/award (A): 28,006 (derivative) · +2 more | EDGAR |
| 2022-02-15 | 4 | Ronsheim Matthew — See Remarks | Disposition to issuer (D): 40,000 (derivative) · Grant/award (A): 33,333 (derivative) | EDGAR |
| 2022-02-15 | 4 | Perros Manoussos — President and CEO | Disposition to issuer (D): 87,462 (derivative) · Grant/award (A): 58,307 (derivative) · Disposition to issuer (D): 166,623 (derivative) · Grant/award (A): 128,531 (derivative) · Disposition to issuer (D): 79,698 (derivative) · Grant/award (A): 44,276 (derivative) · +2 more | EDGAR |
| 2022-02-15 | 4 | Behanna Heather — Director | Disposition to issuer (D): 15,000 (derivative) · Grant/award (A): 11,538 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Grant/award (A): 5,769 (derivative) | EDGAR |
| 2022-02-15 | 4 | Altarac David — Chief Medical Officer | Disposition to issuer (D): 120,000 (derivative) · Grant/award (A): 92.31 (derivative) | EDGAR |
| 2022-02-15 | 4 | Mayer Howard — Director | Disposition to issuer (D): 15,000 (derivative) · Grant/award (A): 12,500 (derivative) | EDGAR |
| 2022-02-15 | 4 | Gutch Michael — See Remarks | Disposition to issuer (D): 30,006 (derivative) · Grant/award (A): 23,081 (derivative) · Disposition to issuer (D): 15,956 (derivative) · Grant/award (A): 8,863 (derivative) · Disposition to issuer (D): 56,500 (derivative) · Grant/award (A): 43,460 (derivative) | EDGAR |
| 2022-02-15 | 4 | Keiley Elizabeth M — General Counsel | Disposition to issuer (D): 25,000 (derivative) · Grant/award (A): 20,833 (derivative) | EDGAR |
| 2022-02-15 | 4 | Meek David D. — Director | Disposition to issuer (D): 15,000 (derivative) · Grant/award (A): 11,538 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Grant/award (A): 5,769 (derivative) | EDGAR |
| 2022-02-15 | 4 | HASTINGS DAVID C — Director | Disposition to issuer (D): 12,060 (derivative) · Grant/award (A): 9,276 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Grant/award (A): 11,538 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Grant/award (A): 5,769 (derivative) | EDGAR |
| 2022-01-19 | 4 | Tommasi Ruben — Chief Scientific Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Ronsheim Matthew — See Remarks | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Perros Manoussos — See Remarks | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Mueller John Patrick — Chief Development Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Behanna Heather — Director | Grant/award (A): 27,500 @ $0 | EDGAR |
| 2022-01-19 | 4 | Altarac David — Chief Medical Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Triola Anna Diaz — Chief Commercial Officer | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Mayer Howard — Director | Grant/award (A): 27,500 @ $0 | EDGAR |
| 2022-01-19 | 4 | Gutch Michael — See Remarks | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Keiley Elizabeth M — General Counsel | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2022-01-19 | 4 | Meek David D. — Director | Grant/award (A): 27,500 @ $0 | EDGAR |
| 2022-01-19 | 4 | HASTINGS DAVID C — Director | Grant/award (A): 27,500 @ $0 | EDGAR |
| 2021-11-03 | 4 | Ronsheim Matthew — Chief, Pharma Sciences & MFG. | Tax withholding (F): 3,669 @ $2.94 | EDGAR |
| 2021-11-03 | 4 | Altarac David — Chief Medical Officer | Tax withholding (F): 3,669 @ $2.94 | EDGAR |
| 2021-11-03 | 4 | Mueller John Patrick — Chief Development Officer | Tax withholding (F): 3,907 @ $2.94 | EDGAR |
| 2021-11-03 | 4 | Perros Manoussos — President and CEO, Director | Tax withholding (F): 11,704 @ $2.94 | EDGAR |
| 2021-11-03 | 4 | Tommasi Ruben — Chief Scientific Officer | Tax withholding (F): 3,669 @ $2.94 | EDGAR |
| 2021-11-03 | 4 | Gutch Michael — CFO and Chief Business Officer | Tax withholding (F): 3,669 @ $2.94 | EDGAR |
| 2021-11-03 | 4 | Keiley Elizabeth M — General Counsel | Tax withholding (F): 3,669 @ $2.94 | EDGAR |
| 2021-10-20 | 4 | Mueller John Patrick — Chief Development Officer | Grant/award (A): 25,000 @ $0 · Sale (S): 4,001 @ $3.19 | EDGAR |
| 2021-10-20 | 4 | Tommasi Ruben — Chief Scientific Officer | Grant/award (A): 25,000 @ $0 · Sale (S): 3,759 @ $3.19 | EDGAR |
| 2021-10-20 | 4 | Altarac David — Chief Medical Officer | Grant/award (A): 25,000 @ $0 · Sale (S): 3,759 @ $3.19 | EDGAR |
| 2021-10-20 | 4 | Ronsheim Matthew — See Remarks | Grant/award (A): 25,000 @ $0 · Sale (S): 3,759 @ $3.19 | EDGAR |
| 2021-10-20 | 4 | Gutch Michael — See Remarks | Grant/award (A): 25,000 @ $0 · Sale (S): 3,759 @ $3.19 | EDGAR |
Recent 8-K events — Entasis Therapeutics Holdings Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-07-11 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-04-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-02-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2022-02-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-01-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2021-11-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2021-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ETTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs